Alpha-1 Antitrypsin Deficiency and Emphysema
Sanofi AATD Inc. focuses its clinical research on alpha-1 antitrypsin deficiency with a specific emphasis on emphysema, reflecting interest in lung disease linked to inherited protein deficiency and progressive respiratory impairment.
- AATD-associated emphysema
- Respiratory disease
- Inherited pulmonary disorders
The sponsor’s trial portfolio is centered on therapeutic approaches aimed at addressing the clinical burden of alpha-1 antitrypsin deficiency in adults with chronic lung involvement.
Alpha-1 Antitrypsin Replacement Therapy
Its research activity includes comparison with plasma-derived A1PI therapy, indicating a therapeutic interest in restoring functional alpha-1 antitrypsin activity for patients with deficient levels.
- Protein replacement therapy
- Functional AAT restoration
- Serum trough AAT levels
This area of work is closely tied to interventions designed to support protease-antiprotease balance in lung tissue.
Chronic Respiratory Disease Management
The sponsor’s clinical interests extend to the management of chronic disease features associated with emphysema, including ongoing assessment of respiratory function and long-term disease control in adults living with AATD.
- Chronic obstructive lung disease
- Progressive airflow limitation
- Pulmonary preservation
These studies reflect a focus on therapies relevant to sustained care in patients with persistent pulmonary injury.
Long-Term Safety and Tolerability
Sanofi AATD Inc. also investigates the long-term safety and tolerability of its respiratory therapies, supporting continued evaluation of treatment suitability in adults with alpha-1 antitrypsin deficiency emphysema.
- Safety monitoring
- Treatment tolerability
- Long-term exposure
Clinical activity in this area is directed toward understanding how therapies perform over extended use in chronic lung disease.
